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HIV and SIV gp120 Binding Does Not Predict Coreceptor Function
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Interaction of HIV and SIV Envelope (Env) proteins with viral coreceptors is a critical step in viral entry. By using a sensitive
and specific gp120 binding assay, we have identified a discordance between the ability of a coreceptor to support
Env-mediated membrane fusion and high-affinity binding of gp120. Direct binding of gp120 from the dual-tropic HIV-1 strain
89.6 was not detectable for any coreceptor that it uses for fusion, while detectable binding of gp120s from the R5 HIV-1
strains JRFL and CM235 and the SIV strain 239 was not measurable for many CCR5 chimeras and mutants that function
efficiently as viral coreceptors. In comparison, binding of chemokines to these same mutants was highly predictive of their
ability to signal. Thus, gp120 is more sensitive than chemokines to perturbations of CCR5 structure. We conclude that while
chemokine binding to CCR5 is a good predictor of chemokine receptor function, gp120 binding does not always predict





























nHuman immunodeficiency virus (HIV) enters cells by a
rocess mediated by the viral Envelope (Env) glycopro-
ein. Env is produced as a gp160 precursor which is then
leaved into a gp120 subunit that mediates receptor
inding and a gp41 subunit that mediates lipid bilayer
ixing. Binding of gp120 to CD4 triggers conformational
hanges in gp120 that lead to the exposure of a core-
eptor binding domain (1). The chemokine receptor
CR5 is the major coreceptor for macrophage-tropic
M-tropic) strains while CXCR4 is the major coreceptor
or T-cell line-tropic strains of HIV-1 (2). Nearly a dozen
ther chemokine or related orphan receptors can also
unction as coreceptors for subsets of HIV-1, HIV-2, and
imian immunodeficiency virus (SIV) strains, though their
n vivo relevance is uncertain (2).
Coreceptor binding is thought to trigger conforma-
ional changes in Env that lead to membrane fusion (1).
hile the regions of CCR5 required to support Env-
ediated membrane fusion have been well studied (re-
iewed in (3)), the regions involved in gp120 binding and
he relationship between gp120 binding and coreceptor
ctivity have been analyzed using only a handful of CCR5
utants (4–9). Part of the difficulty in studying the struc-
ural interactions between gp120 and the coreceptors is
ue to the need to use a direct, rather than a competitive,
inding assay to study complex two-component interac-
1 To whom correspondence and reprint requests should be ad-
ressed at (B.J.D.) 807 Abramson, 34th and Civic Center Boulevard,C
hiladelphia, PA 19104. Fax: (215) 573-2883. E-mail: doranz@mail.
ed.upenn.edu or (R.W.D.) doms@mail.med.upenn.edu.
267ions. A direct chemokine binding assay, for example,
as proven useful in identifying the structures involved in
hemokine–chemokine receptor binding and signaling
10, 11). A direct gp120–CCR5 binding assay has proven
ritical for identifying a highly conserved domain in
p120 implicated in coreceptor interactions (12), and this
nformation may help explain how coreceptor-triggered
orms of Env may generate broadly cross-reactive, po-
ently neutralizing antibodies (13). A direct, rather than
ompetitive, binding assay for detecting gp120–corecep-
or interactions is also particularly useful as a drug dis-
overy tool in high-throughput screening assays. The
tility of a direct binding assay, however, assumes that
p120–coreceptor binding is a functional predictor of
nv–coreceptor interactions. Here we report a surprising
iscordance between gp120–coreceptor binding and
nv-mediated fusion.
Binding of several HIV and SIV gp120–sCD4 com-
lexes directly to CCR5 and CXCR4 has been described
reviously (4, 5, 9, 14). However, binding to other core-
eptors has not yet been demonstrated and only two
trains of HIV-1 gp120, JRFL and YU2, have been shown
o bind directly to CCR5 (4, 5, 9). To examine gp120
inding to additional coreceptors, we produced a recom-
inant vaccinia virus vector that expresses the HIV-1 89.6
p120 subunit. HIV-1 89.6 is a dual-tropic (R5X4) virus
hat efficiently utilizes CCR5 or CXCR4, in conjunction
ith CD4, to infect cells. In addition, the 89.6 Env protein
an mediate infection of cells expressing CD4 and a
umber of alternative coreceptors, including CCR2b,
CR3, CCR8, STRL33, and APJ (2). We used purified,
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268 RAPID COMMUNICATIONadiolabeled 89.6 gp120 in a sensitive and specific bind-
ng assay that we have previously used to measure the
irect interaction of HIV-1 JRFL gp120 with CCR5 (15).
Binding of JRFL gp120 to CCR5 required the presence
f sCD4, exhibited a signal:noise ratio of approximately
0:1, and occurred with a Kd of 4 nM (15). Binding of JRFL
FIG. 1. (A) Iodinated JRFL gp120, produced from recombinant vaccinia
xpressing the indicated receptors, including rhesus CCR5 (rhCCR5) a
eagents is given elsewhere (15). Representative raw values of binding
B) Iodinated 89.6 gp120 was bound to 5 3 105 293T cells transiently t
accinia virus, vBD2, producing 89.6 gp120 was made by inserting a stop
as purified and iodinated as described elsewhere (15). Representative
267 cpm to pcDNA3-transfected cells. All conditions contained 100 n
ackground binding to pDNA3-transfected cells has been subtracted.p120 to other coreceptors was not observed, consistent iith the fusion requirements of JRFL Env for both CCR5
nd CD4 (Fig. 1). In contrast, 89.6 gp120 did not bind to
ny coreceptor that supports infection by HIV-1 89.6 (Fig.
). 89.6 gp120 was, however, capable of binding CD4,
ndicating that it was conformationally intact. We iodin-
ted 89.6 gp120 using three different methods with sim-
was bound to 2 3 105 293T cells transiently transfected with plasmids
rine CCR5 (mCCR5). A detailed description of binding conditions and
8,665 cpm to CCR51sCD4 and 1815 cpm to pcDNA3-transfected cells.
ted with plasmids expressing the indicated receptors. A recombinant
at the cleavage site of 89.6 Env in vaccinia plasmid pSC65, and gp120
lues of binding were 6541 cpm to CD4, 1289 cpm to CCR51sCD4, and
4 except binding to membrane-bound CD4 and “no sCD4” conditions.

















































































































269RAPID COMMUNICATIONeadily detected, while binding to cells expressing core-
eptors alone was not observed. The failure of 89.6
p120 to bind CCR5, CXCR4, or other coreceptors indi-
ates that the inability to detect direct binding of a gp120
rotein to a coreceptor does not necessarily predict
oreceptor function for membrane fusion.
The failure of 89.6 gp120 to bind to CCR5 or CXCR4
as surprising since other studies have suggested that
p120–coreceptor binding correlates well with viral in-
ection. For example, mutations in the N-terminal domain
f CCR5 that prevent binding of JRFL gp120 also block
irus infection (6–8). To determine if the failure of 89.6
p120 to interact with coreceptors was a peculiarity of
his Env protein or if other Env proteins sometimes fail to
ind to coreceptors that support virus infection, we ex-
mined a panel of previously described CCR5/CCR2b
himeras (16) and heterologous CCR5 chimeras (17) for
he ability to bind gp120 and to support virus infection.
he receptor chimeras are named based on the source
f each of their four extracellular domains. Thus, 5222
ontains the amino terminus of CCR5 and the loops of
CR2. Heterologous chimeras are joined at the amino-
erminal Cys present in CCR5, CCR1, CCR2b, CXCR2, and
XCR4 and are named with the amino terminus reflect-
ng the source of the parental receptors. Using a large
anel of CCR5 monoclonal antibodies, we have found
hat all of these constructs are expressed at near-wild-
ype levels on the cell surface (18).
These mutants have previously been characterized for
heir ability to support cell–cell fusion (16, 17). To deter-
ine which supported virus infection, we transiently ex-
ressed each receptor on 293T or U87 cells, added JRFL
r ADA Env-pseudotyped reporter viruses, and measured
uciferase activity 2 days later. Similar to what we and
thers have previously reported (3, 16, 17), multiple do-
ains of CCR5 are important for coreceptor activity, with
he amino-terminal domain and second extracellular
oop being particularly important (Fig. 2A and Table 1).
e then used these CCR5 chimeras in a JRFL gp120
inding assay to identify the domains of CCR5 that are
equired to support gp120 binding. Surprisingly, none of
he receptor chimeras or mutants supported JRFL gp120
inding, even those that supported virus infection with
igh efficiency (Fig. 2B and Table 1). To test whether the
nability of JRFL gp120 to bind these CCR5 mutants was
pecific to this particular virus strain, we also utilized two
ther gp120 proteins that bind to CCR5 (15). CM235
p120 is derived from a clade E M-tropic HIV-1 and 239
p120 is derived from SIVmac239. SIVmac239 is capable
f using many of these chimeras for Env-mediated fusion
19). Binding assays with these proteins yielded results
early identical to those of JRFL gp120, with minimal
inding to all mutants of CCR5 observed (Table 1). Thus,
p120 binding to CCR5 mutants yielded no predictive
alidity of coreceptor function for the HIV-1 or SIV pro-
eins tested. gA subset of the CCR5/CCR2b chimeras used here has
reviously been utilized to map the regions of CCR5
equired for binding of the CCR5 ligand MIP1a (10). To
irectly compare these previous results with our Env
inding and infection results, we performed binding ex-
eriments using three b-chemokine ligands for CCR5,
IP1a, MIP1b, and RANTES. Similar to the results ob-
ained by Samson et al. (10), we found that the second
xtracellular loop of CCR5 was the major determinant of
hemokine interaction (Fig. 2C and Table 1). We also
ound that the CCR5 structures that support binding can
ary for the different b-chemokines (e.g., 2252 and 5255
upport MIP1a and RANTES, but not MIP1b binding). Of
articular note was the ability of the b-chemokines to
ind to many CCR5 chimeras that fail to support detect-
ble gp120 binding (Fig. 2 and Table 1). Importantly,
eceptor constructs that supported chemokine binding
lso supported chemokine-induced receptor signaling,
hile constructs that did not support chemokine binding
lmost always failed to signal (Table 1 and (10)). Thus,
hemokine binding to CCR5 is a good predictor of che-
okine receptor function, while gp120 binding is not a
ood predictor of coreceptor function. We conclude that
p120 binding is more sensitive than chemokine binding
o perturbations in chemokine receptor structure.
While our direct binding results suggest that gp120 is
ot interacting at all with some CCR5 chimeras, our
nfection results clearly indicate that some form of inter-
ction is occurring. Therefore, we performed a JRFL
p120 binding assay under maximal binding conditions
o a truncation mutant of CCR5 missing four amino acids
fter the initiator methionine, CCR5D4, which supports
RFL infection but not gp120 binding. For this assay we
tilized a maximum number of cells (1 3 106) overex-
ressing the coreceptor and demonstrated specificity by
ompeting with excess cold JRFL gp120. While these
onditions are not appropriate for rigorous quantification
f ligand–receptor affinity, we were able to reproducibly
btain a signal above background that demonstrated
pecificity for the receptor (Fig. 3). Our results indicate
hat JRFL gp120 binds to CCR5D4 with an affinity .21
M. In addition, by competition analysis using cold 89.6
p120 and radiolabeled JRFL gp120, we were able to
btain a K i of 220 nM for 89.6 gp120 binding to CCR5
data not shown). The lowest affinity that we have mea-
ured for direct gp120 binding to any CCR5 mutant is
pproximately 30 nM (unpublished data), close to the
heoretical 10–100 nM limit of detectability that filtration-
ased assays can measure (20). These observations
uggest that our inability to measure direct binding of
p120 to other CCR5 mutants, despite the ability of these
utants to support HIV fusion, is due to affinities of
nteraction with gp120 of .30 nM.
Our results also suggest that JRFL gp120 binds to only







dFIG. 2. (A) Infection by JRFL. 293T cells or U87 cells transiently transfected with the indicated coreceptor and CD4 were used for infection with
uciferase-expressing HIV virions pseudotyped with the JRFL Env, as previously described (11, 22). Heterologous chimeras are joined at the
mino-terminal Cys present in CCR5 (5), CCR2b (2), CCR1 (1), CXCR4/Lestr (L), and CXCR2/IL8RB (8). All mutants are expressed at near-wild-type
evels on the surface of the cell, as measured by FACS analysis ((18) and data not shown). (B) JRFL gp120 binding. Iodinated JRFL gp120 was bound
o 2–4 3 105 transiently transfected 293T cells expressing the indicated chimera in the presence of 100 nM sCD4. Background gp120 binding was
efined as binding to cells transfected with pcDNA3 vector alone. (C) Binding of b-chemokines to CCR5 chimeras. Iodinated chemokines
5NEN-Dupont) were bound to 2 3 10 293T cells transiently transfected with the indicated CCR5 chimeras. Background chemokine binding was
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271RAPID COMMUNICATIONild-type CCR5 (430,526 sites/cell), despite the fact that
CR5D4 is expressed nearly as well on the surface as
etected by staining with multiple monoclonal antibodies
18). We have elsewhere demonstrated detectable bind-
ng of JRFL gp120 to CCR5 using as few as 1 3 1010 total
p120 binding sites (15). These observations suggest
hat at least 1 3 1010 receptors for gp120 (comparable to
0,000 binding sites/cell for the experiment in Fig. 3) of
0 nM or higher affinity are necessary for detectable
inding of gp120 to the coreceptors under the conditions
hat we have used. In comparison, between 700 and
000 coreceptors per cell are sufficient to support virus
nfection at near-wild-type levels provided that CD4 ex-
ression is relatively high (21). We speculate that the
nability of previously published coreceptor and Env mu-
ants to interact may be due to similar low-affinity inter-
ctions or recognition failure (5–9, 11, 12). Our results
tress the importance of relating coreceptor binding to
oreceptor-mediated fusion, since loss of binding does
ot necessarily correlate with loss of function.
The extreme sensitivity of gp120 binding to alteration
f CCR5 was not expected given that multiple receptor
lterations are compatible with coreceptor function,
T
Note. Values represent average of experiments repeated at least
ubtracted as in Figs. 1 and 2. Infection values are given as percentage
IP1a (Peprotech) were measured using Ca-flux as described previous
1) .50%, (1/2) 10–50%, (2) ,10%, (nd) not determined.hough we have also reached identical conclusions for phe binding of gp120 to CXCR4 (11). The lack of correla-
ion between Env binding and Env fusion with the core-
eptors may be explained by the natural context in which
usion occurs. HIV uses CD4 as its primary receptor and
hus may not require a coreceptor for high-affinity bind-
ng. In addition, once contact with the chemokine recep-
or occurs, viral fusion may proceed very rapidly when
nv is triggered and the fusion peptide of gp41 inserts
nto the target membrane, making the initial contact with
he coreceptor essentially an irreversible binding step for
he virus. We also note that we have used monomeric
p120, and this can be only partially representative of the
ligomeric structure of Env that is found on the surface of
virus. While the detection sensitivity of monomeric and
ligomeric Env would be expected to be different, the
bility of monomeric and oligomeric Env to utilize the
oreceptors in a fundamentally different way remains to
e tested.
The lack of correlation between gp120 binding and
oreceptor function can be attributed to two distinct
echanisms. First, as demonstrated in this paper, high-
ffinity binding of gp120 to a coreceptor is not necessary
or the coreceptor to support fusion. Thus, a large dis-
alues greater than 10% are shaded. Background binding has been
pe CCR5 without background subtraction. Signaling experiments using
r by microphysiometry (¥, (10)) and are expressed relative to wild type:ABLE 1
twice. V































































272 RAPID COMMUNICATIONo measure direct gp120 binding and Env-mediated fu-
ion, although we note that this same disparity does not
xist between chemokine binding and receptor-medi-
ted signaling through the same sets of chemokine re-
eptor mutants. Second, as we have demonstrated else-
here using a panel of MAbs (18), the structures of CCR5
hat support gp120 binding and Env-mediated fusion
ap to overlapping but distinct regions. Thus, several
mino-terminal MAbs that effectively block gp120 bind-
ng have little effect on fusion, while many CCR5-loop
Abs that effectively block fusion have little effect on
p120 binding.
Our studies with 89.6 suggest a model in which the
bility of 89.6 to utilize multiple coreceptors for fusion
omes at the expense of a high-affinity interaction with
ny single coreceptor, a property reflected in the in-
reased sensitivity of 89.6 and other dual-tropic viruses
o changes in coreceptor structure and to coreceptor
nhibitors (3, 17, 22). We note that this scenario is quite
ifferent from that of chemokines in which a single che-
okine (e.g., MIP1a) can bind to multiple chemokine
eceptors with high affinity (e.g., CCR1, CCR5) and yet is
till not particularly sensitive to changes in coreceptor
tructure (Table 1). Subsequent to these studies, we
ave improved the detection sensitivity of our direct
inding assay even further, in part by using oil separation
f bound radioligand, and have detected a small, but
ignificant, signal of 89.6 gp120 binding to CCR5 in the
resence of sCD4 (data not shown), thus demonstrating
n interaction between the molecules that is clearly just
t the level of sensitivity of detection. Some of the gp120
esidues that compose the conserved chemokine recep-
or binding site (12) are altered in 89.6 gp120. While two
FIG. 3. Binding competition of JRFL gp120 to the CCR5D4 truncation
nd (25)555 chimera. 1 3 106 cells transiently transfected with the
ndicated chemokine receptor mutants were used for binding with 0.35
M iodinated JRFL gp120 for 1 h at room temperature in the presence
f increasing amounts of cold JRFL gp120. Results are fit by nonlinear
egression without any background subtraction.f these residues, F317 and T436 (corresponding to YU2esidues L317 and R440 (12)), are predicted to have a
ignificant effect on CCR5 binding, it is unclear if these
esidues alone explain the reduced affinity of 89.6 for
CR5 or if other residues also contribute to the con-
erved coreceptor binding site.
The sensitivity of gp120 binding to structural changes
n CCR5 has practical implications for ligand choice in
rug screening. For example, a compound that even
lightly alters the structure of CCR5 would be predicted
o have a profound affect on the ability of gp120 to bind
CR5. The effects on chemokine binding would be pre-
icted to be much less severe, an important contrast
iven that first-round compounds are rarely highly active
gainst their targets.
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